Blinatumomab Consolidation for B-Cell Acute Lymphoblastic Leukemia
This study is looking at how well blinatumomab works for adults with B-cell Acute Lymphoblastic Leukemia (B-ALL), a type of blood cancer. Blinatumomab is a bispecific drug, meaning it works by targeting two different things in the body to fight cancer. The study aims to see what percentage of participants achieve complete remission (when all signs of cancer disappear) at 5 years. You might be able to join if you are 18 or older, were diagnosed with B-ALL on or after December 1st, 2023, and haven't received blinatumomab in another clinical trial. This is an observational study, meaning researchers will collect information about your treatment and health over time.
- Study design
- This is an observational study, not a clinical trial where a specific treatment is tested. It plans to include 200 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed to see if they achieve complete remission, measured at 5 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Blinatumomab Consolidation in Real World
At a glance
Conditions
Where it's being run
3 sites across 3 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Percentage of participants with complete remission5 years or e.g., 1 year after closure of study
Complete remission as defined by patients having no lymphoblasts in the marrow or blood